With the BD Nexiva™ Closed IV Catheter System
Median dwell time for BD Nexiva™ IV catheters versus the open-system catheters studied in a randomized trial of PIVCs in place for more than 24 hours.8
A longer dwell time, paired with clinically indicated replacement of PIVCs, can result in:
• Significant reduction in healthcare resource use such as equipment and staff time6
• Minimized number of restarts and costs7
• Increased patient satisfaction7
Integrated extension tubing and stabilization platform† reduce manipulations and movement at the site that may lead to dislodgement‡ and phlebitis1,10
Clinically demonstrated to reduce accidental dislodgement10‡ and complies with the Infusion Therapy Standards of Practice and CDC guidelines for catheter stabilization3,4
98% reduced blood exposure during insertion due to the BD Nexiva™ IV catheter preassembled system10*
Proprietary BD Vialon™ catheter material softens up to 70% in the vein, enabling longer dwell times and reducing the chance of mechanical phlebitis by up to 50%11§
The presence and growth of a pathogenic micro-organism(s) having a local or systemic effect3.
Inflammation of a vein4.
Obstruction of a vascular access device lumen, preventing or limiting the ability to flush and/or administer solutions through a lumen or withdraw blood3.
When the chosen securement method fails, and the catheter becomes displaced.
Inadvertent leakage of a vesicant solution into surrounding tissue4.
Day in the life of a PIV
• Use extension set (integrated preferred) on PVAD (to reduce manipulations and avoid dislodgement).
• Use suture-less securement (including engineered securement devices) to limit movement of VAD. Method of securement can include an integrated stabilization feature on PVAD.
• Use safety-engineered medical sharps.
• Consider using sterile techniques for all PVAD insertions.
• Do not remove VAD based solely on length of dwell time, as optimum dwell time is unknown.
To the patient, complications, and the restarts they require are painful and risky. They can delay treatment and extend length of stay. They negatively impact the overall patient experience and mean additional work and stress for the clinician. Increased IV catheter restarts can have a dramatic impact on the hospital as well. Patient satisfaction is impacted, and the costs of increased product usage and lost efficiency can really add up.
Discover the BD Nexiva™ Closed IV Catheter System, shown to preserve sites for longer and designed to protect patients by reducing the risk of complications and restarts7,8*, and protect you on the job.
Integrated Extension Set
Designed to reduce manipulation and movement at the insertion site and reduce blood exposure during insertion10
Pinch Clamp
Allows one-handed opening and closing of extension set
BD Instaflash™ Needle Technology
A notched needle designed to improve first-stick success and reduce painful hit-and-miss insertions9
Passive Safety Needle-Shielding Mechanism
Prevents needle-stick injuries
BD Vialon™ Catheter Material
Proprietary catheter material enables longer dwell times and reduces the chance of mechanical phlebitis by up to 50%11
Built-in Stabilization Platform
Reduces dislodgement by 84%10
Available in Single- and Dual-Port configuration, with Needle-free connector options
The BD Nexiva™ Closed Peripheral IV Catheter System is the only all-in-one PIVC shown to preserve sites for longer8*. Learn more about the catheter’s unique design and how it can help to reduce complications, dwell longer, and preserve sites. BD Nexiva™ is a passive-safety device with blood containment technology (thanks to its integrated extension set!), designed to protect the healthcare worker.
*Closed system = Fully-integrated system that consists of an integrated extension tube, stabilization platform, and needle-free connectors.
*Compared to an open system.
†When used with an IV site securement dressing.
‡Compared with B. Braun Introcan Safety® catheter with Bard Statlock® IV Ultra stabilization device.
§Compared with an FEP catheter
1. Helm RE, Klausner JD, Klemperer JD, et al. Accepted but unacceptable: peripheral IV catheter failure. Infus Nurs Society. 2015;38(3):189-203.
2. Canadian Vascular Access Association. (2019). Canadian Vascular Access and Infusion Therapy Guidelines. Pembroke, ON: Pappin Communications.
3. Gorski LA, Hadaway L, Hagle ME, et al. Infusion therapy standards of practice. J Infus Nurs. 2021;44(suppl 1):S1-S22
4. O’Grady NP, Alexander, M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. CDC. 2011:16
5. Alexander M, Corrigan A, Gorski L, et al. Infusion Nursing: An Evidence-Based Approach. 3rd ed. St. Louis, MO: Saunders Elsevier; 2010:213, 410.
6. Tuffaha H, Rickard C, Scuffham P, et al. Cost-effectiveness analysis of clinically indicated versus routine replacement of peripheral intravenous catheters. Appl Health Econ Health Policy. 2014;12(1):51-58.
7. Rickard CM, Webster J, Wallis MC, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet. 2012;380(9847):1066-107
8. González López J, Arribi Vilela A, Fernández Del Palacio E, et al. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. J Hosp Infect. 2014;86(2):117-126.
9. van Loon FH, Timmerman R, den Brok GP, Korsten EH, Dierick-van Daele AT, Bouwman AR. The impact of a notched peripheral intravenous catheter on the first attempt success rate in hospitalized adults: Block-randomized trial. The Journal of Vascular Access. 2022;23(2):295-303.
10. Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheterstabilization systems. J Infus Nurs. 2010;33(6):371-384.
11. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. Ann Intern Med. 1991;114(10):845-85
BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy.
